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Introduction {#acn3622-sec-0001}
============

Intellectual disability (ID) affects 1--3% of the population and is more prevalent in males versus females.[1](#acn3622-bib-0001){ref-type="ref"} Although over 100 genes on the X chromosome were found to be associated with ID in males,[2](#acn3622-bib-0002){ref-type="ref"}, [3](#acn3622-bib-0003){ref-type="ref"} relatively less is known about X‐linked ID genes in females.[4](#acn3622-bib-0004){ref-type="ref"} Whole‐exome sequencing (WES) is finding *de novo* variants in X‐linked ID genes in females of all ages.[5](#acn3622-bib-0005){ref-type="ref"}, [6](#acn3622-bib-0006){ref-type="ref"}, [7](#acn3622-bib-0007){ref-type="ref"}, [8](#acn3622-bib-0008){ref-type="ref"} However, limited information is available regarding such cases. Some of the genes causing ID in females are known to cause disease in males, including *PHF6,* [9](#acn3622-bib-0009){ref-type="ref"} *NEXMIF,* [8](#acn3622-bib-0008){ref-type="ref"} and *USP9X*, with the latter causing congenital malformations not observed in affected males.[10](#acn3622-bib-0010){ref-type="ref"} Further evidence for gender‐specific variant pathogenicity comes from *DDX3X* located on Xp11.4, with pathogenic *de novo* variants causing syndromic ID in 39 females; in the same study, three males inherited *DDX3X* variants from apparently unaffected mothers.[11](#acn3622-bib-0011){ref-type="ref"} Differences in predicted variant severity or X‐chromosome inactivation studies from blood DNA did not explain the gender‐specific disease expression. Five additional females with *DDX3X* variants have been described in the literature.[12](#acn3622-bib-0012){ref-type="ref"}, [13](#acn3622-bib-0013){ref-type="ref"}, [14](#acn3622-bib-0014){ref-type="ref"} These reports led us to hypothesize that females with *de novo* variation in *DDX3X* may show additional clinical phenotypes. We report 31 individuals with *DDX3X*‐related disorders, and provide comprehensive clinical presentations for 13, including expanding the age range of molecular diagnosis with the oldest reported individual and a fetus. These data expand the number of *DDX3X* pathogenic variants and their associated phenotypic spectrum.

Methods {#acn3622-sec-0002}
=======

Variants in *DDX3X* were identified by WES, performed according to previously described methods,[5](#acn3622-bib-0005){ref-type="ref"}, [6](#acn3622-bib-0006){ref-type="ref"}, [13](#acn3622-bib-0013){ref-type="ref"} either on a clinical basis at Baylor Genetics (Females 1--24, Males 1--2, Fetus 1) or on a research basis by the Baylor Hopkins Center for Mendelian Genomics (BHCMG, Females 25--27) or through the Centre de Génétique Humaine, Université de Franche‐Comté (Female 28). Deidentified reporting of aggregated demographic and molecular data for all clinically referred cases was approved by the Institutional Review Board at Baylor College of Medicine (BCM). Additional, informed consent for publication of clinical details was obtained for a subset of clinically referred cases and all research‐based cases according to IRB‐approved protocols: at Baylor College of Medicine (Female 8, 14, 17, 23, 24, 26), through the Undiagnosed Diseases Network (UDN) protocol (Female 13), and through the BHCMG (Females 7, 19, 25, 27); and at Centre de Génétique Humaine, Université de Franche‐Comté (Female 28). Females 7 and 19 were previously reported in a study of research‐based reanalysis of clinical WES data.[13](#acn3622-bib-0013){ref-type="ref"} *DDX3X* variants were annotated using transcript NM_001193416. Variant pathogenicity was determined based on the ACMG guidelines[15](#acn3622-bib-0015){ref-type="ref"} and the internal guidelines developed at Baylor Genetics (<https://www.baylorgenetics.com/variant-classification/>). For the interpretation of *de novo* variants, the PS2 evidence is used if rare and/or private variants in the proband were detected in both parents by WES (Trio WES) or Sanger sequencing (proband only WES). Otherwise the PM6 evidence is used. 0.1--1 *μ*g total RNA from patient fibroblast cells was extracted for library preparation with TruSeq Stranded mRNA kit and was sequenced by Illumina NextSeq 550. Genes with expression at the top/bottom 5% were used for pathway enrichment analysis by Ingenuity Pathway Analysis (IPA, QIAGEN Inc., <https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis>).

Results {#acn3622-sec-0003}
=======

Among 4839 (2152 females, 2687 males) patients referred to the Baylor Genetics laboratory for clinical WES with developmental delay (DD) and/or ID, 26 postnatal individuals (24 females, 2 males) were found to carry pathogenic or likely pathogenic variants in *DDX3X*, and 1 female fetus was found to carry a *de novo* variant of unknown significance in *DDX3X*. Through collaboration with the BHCMG and Centre de Génétique Humaine, Université de Franche‐Comté, an additional four unrelated female cases (Females 25--28) were identified. The ages at molecular diagnosis of the postnatal individuals ranged from 1 to 47 years (Table [S1](#acn3622-sup-0002){ref-type="supplementary-material"}). Twenty‐nine unique variants were identified (26 novel and 3 reported previously), including 13 missense, 6 frameshift, 3 splice site, 4 nonsense, and 3 in‐frame deletion/duplication changes (Table [1](#acn3622-tbl-0001){ref-type="table"} and Fig. [1](#acn3622-fig-0001){ref-type="fig"}A and B). In 29 individuals with available parents (27 female, 1 male, 1 fetus), the *DDX3X* variants were confirmed as *de novo*, supporting the variant pathogenicity. Two *de novo* variants, c.573_575del (p.I191del) and c.1805G\>A (p.R602Q) are mosaic in the proband, with allele fractions of 21% and 14%, respectively (Table [1](#acn3622-tbl-0001){ref-type="table"}). The most frequent clinical presentations in the 28 females include DD and/or ID (28/28), hypotonia (19/28), dysmorphic features (19/28), structural brain abnormalities (18/20 who had brain MRI, Fig. [S1](#acn3622-sup-0001){ref-type="supplementary-material"}), movement disorders (17/28), visual impairments (9/28), and microcephaly (7/28) (Table [2](#acn3622-tbl-0002){ref-type="table"}). The most commonly observed dysmorphic facial features include a high‐arched palate (5/19), thin upper lip (5/19), large ears (5/19), and long/smooth/large philtrum (4/19). Clinical presentations that are not present in published studies include respiratory problems (5/28): obstructive sleep apnea, tachypnea, and chronic respiratory failure, as well as congenital heart disease (5/7 who had echocardiogram): atrial/ventricular septal defect, double orifice mitral valve with small patent ductus arteriosus, mild concentric left ventricular hypertrophy and bicuspid aortic valve. In comparison to published data, autism spectrum disorder and other behavior problems and skin abnormalities are underrepresented in our cohort (Table [2](#acn3622-tbl-0002){ref-type="table"}). For 13 subjects, we obtained additional informed consent and provide detailed clinical descriptions (Table [S1](#acn3622-sup-0002){ref-type="supplementary-material"}), as well as clinical images for two subjects (Fig. [1](#acn3622-fig-0001){ref-type="fig"}D).

###### 

Subjects with causal variants in *DDX3X*

  Subject     Genotype[a](#acn3622-note-0008){ref-type="fn"}   Inheritance                                        Nucleotide change      Amino acid change   Mutant/total reads by WES   WES type   Variant interpretation                                                  SIFT                        Polyphen2           Mutation taster   Scaled CADD score   Ref
  ----------- ------------------------------------------------ -------------------------------------------------- ---------------------- ------------------- --------------------------- ---------- ----------------------------------------------------------------------- --------------------------- ------------------- ----------------- ------------------- -----------------------------------------
  Female 1    Het                                              *De novo*                                          c.14_17delCAGT         p.A5 fs             93/203                      Trio       Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                34                  
  Female 2    Het                                              *De novo*                                          c.949T\>C              p.C317R             130/265                     Proband    Likely pathogenic, PS2, PM2, PP3                                        deleterious                 probably damaging   disease causing   27.9                
  Female 3    Het                                              *De novo*                                          c.126_129delTTTA       p.H42 fs            38/88                       Proband    Pathogenic, PVS1, PM2, PM6                                              NA                          NA                  NA                33                  
  Female 4    Mosaic 21%                                       *De novo*                                          c.573_575del           p.I191del           69/327                      Proband    Likely pathogenic, PS2, PM2                                             NA                          NA                  NA                22.3                
  Female 5    Het                                              *De novo*                                          c.1244T\>A             p.I415N             205/435                     Proband    Likely pathogenic, PS6, PM2, PP3                                        deleterious                 probably damaging   disease causing   31                  
  Female 6    Het                                              *De novo*                                          c.971C\>G              p.P324R             146/292                     Proband    Likely pathogenic, PS2, PM2, PP3                                        deleterious                 probably damaging   disease causing   28.3                
  Female 7    Het                                              *De novo*                                          c.1703C\>T             p.P568L             239/448                     Proband    Pathogenic, PS2, PS4, PM1, PM2, PP3, PP5                                deleterious                 probably damaging   disease causing   34                  [13](#acn3622-bib-0013){ref-type="ref"}
  Female 8    Het                                              *De novo* [b](#acn3622-note-0009){ref-type="fn"}   c.336dupC              p.R113 fs           107/233                     Proband    Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                33                  
  Female 9    Het                                              *De novo*                                          c.873_874insTATA       p.R292 fs           97/257                      Proband    Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                35                  
  Female 10   Het                                              *De novo*                                          c.874C\>T              p.R292\*            119/229                     Proband    Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                39                  
  Female 11   Het                                              *De novo*                                          c.887G\>C              p.R296P             183/407                     Proband    Likely pathogenic, PS2, PM2, PP3                                        deleterious                 probably damaging   disease causing   34                  
  Female 12   Het                                              *De novo*                                          c.1180_1185dupCGTGAT   p.R394_D395dup      70/182                      Proband    Likely pathogenic, PS2, PM2                                             NA                          NA                  NA                19.5                
  Female 13   Het                                              *De novo*                                          c.1600C\>T             p.R534C             30/88                       Proband    Pathogenic, PS2, PS4, PM1, PM2, PP3                                     deleterious                 probably damaging   disease causing   31                  
  Female 14   Het                                              *De novo*                                          c.1600C\>T             p.R534C             50/114                      Proband    Pathogenic, PS2, PS4, PM1, PM2, PP3                                     deleterious                 probably damaging   disease causing   31                  
  Female 15   Mosaic 14%                                       *De novo*                                          c.1805G\>A             p.R602Q             19/137                      Trio       Likely pathogenic, PS2, PM2, PP3                                        deleterious                 probably damaging   NA                27.9                
  Female 16   Het                                              *De novo*                                          c.1804C\>T             p.R602\*            67/141                      Proband    Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                51                  
  Female 17   Het                                              *De novo*                                          c.453_454del           p.S152 fs           173/372                     Proband    Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                34                  
  Female 18   Het                                              *De novo*                                          c.173C\>A              p.S58\*             53/100                      Proband    Pathogenic, PVS1, PM2, PM6                                              NA                          NA                  NA                36                  
  Female 19   Het                                              *De novo*                                          c.192dupA              p.D65 fs            98/210                      Proband    Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                34                  [13](#acn3622-bib-0013){ref-type="ref"}
  Female 20   Het                                              *De novo*                                          c.1595C\>T             p.T532M             79/171                      Proband    Likely pathogenic, PS6, PM2, PP3                                        deleterious                 probably damaging   disease causing   33                  
  Female 21   Het                                              *De novo*                                          c.1033G\>C             p.V345L             79/155                      Proband    Likely pathogenic, PS2, PM2, PP3                                        deleterious                 possibly damaging   disease causing   26.6                
  Female 22   Het                                              No parental samples                                c.1386C\>G             p.Y462\*            159/342                     Proband    Likely pathogenic, PVS1, PM2                                            NA                          NA                  NA                37                  
  Female 23   Het                                              *De novo*                                          c.284+1G\>A            p.?                 95/191                      Proband    Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                26.9                
  Female 24   Het                                              *De novo*                                          c.865‐1G\>A            p.?                 58/163                      Proband    Pathogenic, PVS1, PS2, PM2                                              NA                          NA                  NA                24.6                
  Female 25   Het                                              *De novo*                                          c.1021T\>C             p.C341R             65/126                      Trio       Likely pathogenic, PS2, PM2, PP3                                        deleterious                 damaging            disease causing   26.4                
  Female 26   Het                                              *De novo*                                          c.1244T\>A             p.I415N             46/87                       Proband    Likely pathogenic, PS6, PM2, PP3                                        deleterious                 damaging            disease causing   31                  
  Female 27   Het                                              *De novo*                                          c.1206_1208delCTT      p.F402del           108/235                     Trio       Likely pathogenic, PS2, PM2, PP3                                        NA (Provean: deleterious)   NA                  disease causing   18.88               
  Female 28   Het                                              *De novo*                                          c.1438A\>G             p.R480G             1821/3806                   Trio       Likely pathogenic, PS2, PM2, PP3                                        deleterious                 probably damaging   disease causing   25.6                
  Male 1      Hemi                                             From asymptomatic mother                           c.1052G\>A             p.R351Q             50/50                       Proband    Likely pathogenic, PS6, PM2, PP5                                        deleterious                 benign              NA                25.1                [11](#acn3622-bib-0011){ref-type="ref"}
  Male 2      Hemi                                             *De novo*                                          c.443+3A\>T            p.?                 87/88                       Proband    Likely pathogenic, PS2, PM2                                             NA                          NA                  NA                13.91               
  Fetus 1     Het                                              *De novo*                                          c.1304T\>C             p.L435P             260/513                     Trio       Variant of unknown significance, PS2, PM2, phenotypic match uncertain   deleterious                 probably damaging   NA                28.4                

Variant interpretation column contains the clinical significance of the variant and the type of evidences supporting the interpretation based on the ACMG guidelines[15](#acn3622-bib-0015){ref-type="ref"} and the internal guidelines developed at Baylor Genetics (<https://www.baylorgenetics.com/variant-classification/>).

NA: not applicable.

WES type: Trio: trio WES; Proband: proband only WES.

None of the variants above has been seen in ExAC (<http://exac.broadinstitute.org/>) or gnomAD.[22](#acn3622-bib-0022){ref-type="ref"}

Het: heterozygous. Hemi: hemizygous.

Heterozygous in the similarly affected monozygotic twin sibling, negative in two other siblings.

John Wiley & Sons, Ltd

![Location of *DDX3X* variants identified in this study, Female individuals (25, 26, 27) ascertained through the BHCMG, and muscle biopsy results in Female 17 showing abnormal mitochondrial morphology. (A) Schematic view of the *DDX3X* exon--intron structure based on NM_001193416. Blue boxes represent exons and yellow fields represent introns. Exon number is listed below each exon. cDNA change is listed for each variant. (B) Schematic view of the DDX3X protein structure based on Snijders Blok et al.[11](#acn3622-bib-0011){ref-type="ref"} Amino acid change is listed for each variant. (C) Pedigree and Sanger tracings demonstrate de *novo* inheritance in three unrelated female probands. (D) Female 25 demonstrated synophrys, a broad nasal root with upturned nostrils, a long philtrum, and thin upper lip. Female 27 demonstrated cupped ears, a long philtrum, and a thin upper lip. (E--G) Muscle biopsy results in Female 17 (E) Skeletal muscle cross‐section showing mild variation in fiber size (H&E; magnification ×400). (F) Skeletal muscle cross‐section showing few fibers with mild subsarcolemmal increase in oxidative activity \[cytochrome oxidase (long arrow) and NADH tetrazolium reductase (inset -- arrow heads; magnifications ×400)\]. (G) Electron microscopic images showing mild subsarcolemmal mitochondrial proliferation (long arrow) with inset in the upper corner showing pleomorphic abnormally elongated and irregularly shaped mitochondria (arrow heads). Variant color in (A) and (B): black, first reported in this study; purple, previously reported. The c.1304T\>C (p.L435P) variant from Fetus 1 was not listed in (A) and (B).](ACN3-5-1277-g001){#acn3622-fig-0001}

###### 

Comparison of clinical presentations in this study and in the published cohort

  Clinical features                                                                             Number of subjects in this study   Percentage in this study   Percentage in the published cohort
  --------------------------------------------------------------------------------------------- ---------------------------------- -------------------------- ------------------------------------
  DD and/or ID                                                                                  28/28                              100%                       100%
  Hypotonia                                                                                     19/28                              68%                        76%
  Dysmorphic features                                                                           19/28                              68%                        NA
  Structural brain abnormalities                                                                18/20                              90%                        81%
  Movement disorders                                                                            17/28                              61%                        45%
  Visual impairments                                                                            9/28                               32%                        34%
  Microcephaly                                                                                  7/28                               25%                        32%
  Autism spectrum disorders and other behavior problems[a](#acn3622-note-0011){ref-type="fn"}   6/28                               21%                        53%
  Respiratory problems                                                                          5/28                               18%                        NA
  Congenital heart disease                                                                      5/7                                71%                        NA
  Skin abnormalities[a](#acn3622-note-0011){ref-type="fn"}                                      5/28                               18%                        37%

NA, not specified or reported in the published study.[10](#acn3622-bib-0010){ref-type="ref"}

In comparison to published data, autism spectrum disorder and other behavior problems and skin abnormalities are underrepresented in our cohort: 6*/*28 versus 20/38 (*P *=* *5.2 × 10^−3^) and 5/28 versus 14/38 (*P *=* *4.6 × 10^−2^), respectively. One‐tailed *Z* score test for two population proportions is used.

John Wiley & Sons, Ltd

In two subjects undergoing muscle biopsy, skeletal muscle mitochondrial DNA content was reduced. The first subject (Female 17) is a 6‐year‐old nondysmorphic girl with a history of neonatal hypotonia, esophageal reflux, and global developmental delay. A quadriceps muscle biopsy demonstrated mild fiber type variation and abnormal pleomorphic mitochondria on electron microscopy (Fig. [1](#acn3622-fig-0001){ref-type="fig"}E--G). After correction for the reduced citrate synthase activity, respiratory chain enzyme activity analysis demonstrated reductions of multiple complexes, with relative sparing of complex II activity. Sequencing of mitochondrial DNA from the muscle sample did not detect any known or likely pathogenic variants. Mitochondrial DNA content in muscle was 39% of age‐matched control muscle. Clinical WES demonstrated a *de novo* heterozygous c.453_454del (p.S152 fs) pathogenic variant in *DDX3X*, with no other variants in known disease‐associated genes that explain the patient\'s clinical presentations. The second subject is a 47‐year‐old woman (Female 13) with history of global developmental delay, intellectual disability, short stature, dysmorphic features, microcephaly, and unilateral renal agenesis. She learned to sit at two years of age and walk at eight, and she only learned to say simple words. In her early 40 sec, she regressed, becoming nonverbal and unable to ambulate or to use her arms. She was found to carry a *de novo* heterozygous c.1600C\>T (p.R534C) pathogenic variant in *DDX3X* (Table [1](#acn3622-tbl-0001){ref-type="table"}). The same variant was also observed in Female 14 in our cohort, and a variant involving the same codon (p.R534H) has been reported in a patient with ID.[11](#acn3622-bib-0011){ref-type="ref"} A quadriceps muscle biopsy demonstrated severe mitochondrial and lipid depletion, and reduction in mitochondrial size similar to Female 17. Mitochondrial DNA content in muscle was 26% of the mean value for age‐ and tissue‐matched controls. A reduction in all mitochondrial respiratory chain complex activities was observed. However, the reduction do not meet diagnostic criteria after correction for the low citrate synthase activity.

Discussion {#acn3622-sec-0004}
==========

Normal RNA metabolism requires the function of RNA helicases (RH), and yet, the exact function of most human RH remains unknown. There are six superfamilies of RH known with more than 50 human members in superfamily two that are characterized by a DExH and DExD signature in their Walker B motifs, thus termed DHX and DDX proteins. Genetic studies have begun to address the role of altered RH function in human disease (e.g., *DHX37* and *DHX30*).[16](#acn3622-bib-0016){ref-type="ref"}, [17](#acn3622-bib-0017){ref-type="ref"} *DDX3X* encodes a DEAD‐box RNA helicase important in transcription, splicing, RNA transport, and translation.[18](#acn3622-bib-0018){ref-type="ref"}, [19](#acn3622-bib-0019){ref-type="ref"} In a diagnostic laboratory referral cohort of 4839 subjects with DD and/or ID, we have identified 26 postnatal individuals (24 females, 2 males) with syndromic ID or DD carrying pathogenic or likely pathogenic variants in *DDX3X*, and one fetus with abnormal ultrasound findings carrying a *de novo* variant of unknown significance in *DDX3X*; an additional four females were identified through research WES at BHCMG. The overall frequency of pathogenic or likely pathogenic *DDX3X* variations in our diagnostic laboratory referral cohort is 0.54% of the total (26/4839) and 1.12% of females (24/2152), similar to a previous report (0.6% and 1.5% respectively),[10](#acn3622-bib-0010){ref-type="ref"} confirming mutations in *DDX3X* are one of the most common genetic causes of unexplained ID in females. In our diagnostic laboratory, *DDX3X* ranks third among approximately 450 genes for the occurrence of *de novo* variants, with *ARID1B* first (43 individuals) and *ANKRD11* sec (29 individuals).

In addition to confirming and extending published mutational data, our phenotypic analyses expand the phenotypic spectrum associated with *DDX3X* variants in females. For instance, we found respiratory problems and congenital heart disease in 5/28 and 5/7 of our subjects, phenotypes not previously described in the original description of *DDX3X* related disorders,[11](#acn3622-bib-0011){ref-type="ref"} although observed in a subsequent report of two females.[12](#acn3622-bib-0012){ref-type="ref"} We found no evidence for genotype--phenotype correlations between the mutations we identified and age at onset or phenotypic severity. Previously reported individuals ranged in ages from 1 to 33 years. We report the phenotype of a 47‐year‐old woman (Female 13) who had manifestations consistent with *DDX3X* disorder and a clinical picture of previously unreported late‐onset neurologic decline. The decline is unrelated to intercurrent illness, and her motor function is at least in part responsive to physical therapy. Of note, other X‐linked DD/ID loci, exemplified by female *FMR1* premutation \[MIM: 300623\] and *MECP2* duplication carriers,[20](#acn3622-bib-0020){ref-type="ref"} are notable for late adult onset neurological or neurocognitive phenotypes.

Two variants reported in this study, c.1600C\>T (p.R534C) and c.1703C\>T (p.P568L), and three previously reported, c.641T\>C (p.I214T), c.931C\>T (p.R311\*), and c.1084C\>T (p.R362C),[11](#acn3622-bib-0011){ref-type="ref"} have also been observed to occur somatically in association with medulloblastoma, malignant melanoma, and esophageal squamous cell carcinoma (<http://cancer.sanger.ac.uk/cosmic>). Malignancy has not been reported in the 31 patients included in this study. However, pathway analysis for the highest 5% and lowest 5% genes expressed in RNAseq data from dermal fibroblasts obtained in one subject (Female 13) showed enrichment in cell cycle control of chromosomal replication and double‐strand break repair pathways (Table [S2](#acn3622-sup-0003){ref-type="supplementary-material"}). Future studies will elucidate whether individuals carrying *DDX3X* variants are at risk for the development of malignancies.[21](#acn3622-bib-0021){ref-type="ref"} In summary, we identified 31 unrelated patients with causal variants in *DDX3X* and expanded the genotypic and phenotypic spectrum of *DDX3X*‐related disorders. The collective data suggest that *DDX3X* defects are a frequent cause of syndromic ID in females, and the causal variants are likely to be loss‐of‐function (ExAC database showed pLI = 1.00 for *DDX3X*).[22](#acn3622-bib-0022){ref-type="ref"}
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**Figure S1.** Brain MRI images of subjects with *DDX3X* variants.
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**Table S1.** Clinical features and *DDX3X* variants in subjects enrolled in this study. Detailed clinical features are only reported for the subjects in whom we were able to obtain additional informed consent.
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**Table S2.** RNAseq pathway analysis for Female 13.
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**Table S3.** Members of the Undiagnosed Diseases Network.
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